中文版English

Home | Add to Favorites | Contact Us

Home >> Department >> Innovation Platform >> Beijing Key Laboratory of Active Substance Discovery and Druggabili…

Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation

 

Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation was founded in 2011, comprising of a number of research groups from Department of Synthetic Medicinal Chemistry, Department of New Drug R&D, and Department of Drug Metabolism. The key laboratory focuses on discovering biologically active substance and extensive evaluating the druggability of lead compounds in the early stage of drug discovery and development to improve the efficiency of research efforts and productivity of novel drug discovery. Hopefully, a model of integrating basic research and applied research can be established in the field of novel drug discovery in China.
The director of this laboratory is Professor Dali Yin, and the director of the academic committee is Professor Liang Huang, academician of Chinese Academy of Sciences. Presently there are about 50 researchers in this laboratory, including one academician of Chinese Academy of Sciences, one specially-appointed professor of Yangtze Scholars, 9 full professors, 10 associate professors, among which 8 are Ph.D. supervisors and 5 are M.S. supervisors.
This laboratory focuses on the R&D of the therapeutic drugs in the field of cancer, cardiovascular and cerebrovascular diseases, diabetes, psychiatric and neurologic diseases, autoimmune diseases, and infectious diseases through the combination of the application of concepts and technology of modern drug R&D in the discovery of bioactive molecules and the ensuing systematic druggability investigation. The key research interests include:
1. Design and optimization of “drug-like” small molecules;
2. Structural modification and development of bioactive natural products;
3. Construction and optimization of druggable small molecules bearing “privileged skeleton” ;
4. The early-stage ADMET properties evaluation and druggability investigation of bioactive small molecules.
Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation has been supported by many important research grants including international projects (NIH, TB Alliance, Gates Foundation, etc.), the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, the national “863” and “973” projects, and the major and key projects of the National Nature Science Foundation of China. Since its establishment in 2011, more than 30 postgraduates have obtained Ph. D. degrees, and approximately 100 research papers have been published, more than 90% of which are SCI cited. Besides, the number of patent applications was more than 30, among which seven were licensed. There are five research platforms in this laboratory including the Platform of Virtual Screening and Structure- & Mechanism-based Drug design, the Platform of Chiral Drug Preparation, the Platform of the Synthesis and Structural Modification of Bioactive Natural Products, the Platform of Combinatorial Chemistry and Chemical Biology, and the Platform of Drug Metabolism and Toxicological Appraisal. The continuing efforts in the related fields of drug discovery have resulted in a number of significant achievements.
On the basis of the research features of the groups in this laboratory, the research mainly focuses on the R&D in the area of anticancer, anti-diabetes, anti-infection (including anti-tuberculosis), anti-inflammation and immunological, and psychiatric and neurologic diseases. Novel chemical entities will be designed, structurally optimized, and comprehensively evaluated according to the modern international standard. With the solid support of Institute of Materia Medica, Chinese Academy of Medical Sciences, it is expected that the input of investigation fund will be increased, and the recruitment of various scientific talents will also be accelerated. The open-running pattern of Beijing Key Laboratory of Active Substance Discovery and Druggability will be deepened through the following measures: insisting on the educational idea of being open to the public and serving the society; constructing a resources-sharing platform of cooperative R&D and education; initiating multi-dimension cooperation and construction with several Beijing municipal pharmaceutical enterprises with the aim of better serving the pharmaceutical industry of Beijing.